Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680758 | 0.94 | LMNA (0.39) | ABCB1CDC7ALDH1A1ADORA1ADORA2A | |
| SCHEMBL5555331 | 0.93 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DCDC7 | |
| SCHEMBL954434 | 0.91 | ABCB1 (0.41) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL64690 | 0.89 | ABCB1 (0.42) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL12293879 | 0.89 | ABCB1 (0.42) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL20841749 | 0.89 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL10196893 | 0.89 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL2680751 | 0.87 | ABCB1 (0.40) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL20841761 | 0.87 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 | |
| SCHEMBL10196888 | 0.87 | ABCB1 (0.39) | ABCB1CDC7ALDH1A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| CN-106148362-B | Novel coelenterazine substrates and methods of use thereof | 普罗梅加公司 | 2021-04-30 | — | — | CN | disclosed |
| US-8669103-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2635595-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| US-20120174242-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-07-05 | — | — | US | disclosed |
| WO-2012061530-A2 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061529-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120117667-A1 | NOVEL COELENTERAZINE SUBSTRATES AND METHODS OF USE | RNGTT, UPF1, NSUN2 | ABCB1 3744/4885PDE4A 259/4885PDE4B 678/4885 |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ABCB1 3400/4885PDE4A 200/4885PDE4B 671/4885 |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | ABCB1 3400/4885PDE4A 200/4885PDE4B 671/4885 |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | ABCB1 3400/4885PDE4A 200/4885PDE4B 671/4885 |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ABCB1 3400/4885PDE4A 200/4885PDE4B 671/4885 |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | ABCB1 3400/4885PDE4A 200/4885PDE4B 671/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | ABCB1 1723/4885PDE4A 259/4885PDE4B 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.